<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034016</url>
  </required_header>
  <id_info>
    <org_study_id>TREC2019-30.A2</org_study_id>
    <nct_id>NCT05034016</nct_id>
  </id_info>
  <brief_title>The Exploratory Clinical Trials on the Primary Safety and Effectiveness of High Myopic Posterior Scleral Fixation System</brief_title>
  <official_title>High Myopic Posterior Scleral Fixation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GuangZhou WeiShiBo Biotechnology Co., ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GuangZhou WeiShiBo Biotechnology Co., ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the primary safety and efficacy of High Myopic&#xD;
      Posterior Scleral Fixation System in the treatment of macular schisis caused by high myopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posterior Scleral Reinforcement（PSR） is the only surgical method that can delay the the&#xD;
      development of high myopia. However, The surgical method is restricted by the material source&#xD;
      limitation and macular ischemia in the eye after reinforcement. The investigators have&#xD;
      designed a new posterior scleral fixation system，Its basic material is medical silicone，The&#xD;
      product is designed to solve the problem of material source limitation and macular ischemia&#xD;
      in the eye after reinforcement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">April 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular reduction rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>24 weeks after implantation of the High Myopic Posterior Scleral Fixation System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>Baseline (Before surgery), 1 day, 1 week, 4 weeks, 12 weeks, 24 weeks,</time_frame>
    <description>ETDRS table</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axial length</measure>
    <time_frame>Baseline (Before surgery), 24 weeks after surgery</time_frame>
    <description>A-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diopter</measure>
    <time_frame>Baseline (Before surgery), 24 weeks after surgery</time_frame>
    <description>Refractometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>High Myopia</condition>
  <condition>Macular Schisis</condition>
  <arm_group>
    <arm_group_label>HM experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraocular implant test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural observation control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Natural observation of the disease changes, no surgical intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Myopic Posterior Scleral Fixation System</intervention_name>
    <description>Implant HM into the eye through posterior scleral reinforcement</description>
    <arm_group_label>HM experimental group</arm_group_label>
    <other_name>HM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18~65, male or female;&#xD;
&#xD;
          2. Refractive ranges from -6.00d to -25.00d;&#xD;
&#xD;
          3. The axial length of the operative eye was 26-32mm;&#xD;
&#xD;
          4. Macular cleavage 200-1000μm;&#xD;
&#xD;
          5. Corrected visual acuity of the operative eye &lt; 0.3;&#xD;
&#xD;
          6. Able to understand the purpose of the test, voluntarily participate and sign the&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to silica gel and patients with scar constitution;&#xD;
&#xD;
          2. Ocular inflammation;&#xD;
&#xD;
          3. Fundus hemorrhage;&#xD;
&#xD;
          4. Macular hole;&#xD;
&#xD;
          5. Macular cleavage of the contralateral eye greater than 200μm;&#xD;
&#xD;
          6. Corrected visual acuity of contralateral eye &lt; 0.4;&#xD;
&#xD;
          7. Opacity of the refractive medium;&#xD;
&#xD;
          8. Eye tumor;&#xD;
&#xD;
          9. History of hyperthyroidism;&#xD;
&#xD;
         10. Other ophthalmic concomitant diseases that cannot be controlled, such as diabetic&#xD;
             retinopathy, hypertensive fundus lesions, optic nerve atrophy, etc.;&#xD;
&#xD;
         11. Severe impairment of liver and kidney function and/or severe systemic diseases (such&#xD;
             as cardiovascular, respiratory, digestive, nervous, endocrine, genitourinary, etc.,&#xD;
             depending on the tolerance of surgery);&#xD;
&#xD;
         12. Women who are pregnant (determined by a blood pregnancy test at the first visit), who&#xD;
             are preparing for pregnancy during the test, and who are breastfeeding;&#xD;
&#xD;
         13. a history of drug abuse or alcohol abuse;&#xD;
&#xD;
         14. participate in other drug or medical device clinical trials within 30 days prior to&#xD;
             the screening of this clinical trial;&#xD;
&#xD;
         15. Any condition of the subject that the study physician considers to be an impediment to&#xD;
             the clinical trial (e.g. subject's susceptibility to mental stress, uncontrollable&#xD;
             mood, depression, etc.);&#xD;
&#xD;
         16. Poor compliance of the subject, unable to complete the test process as required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbing Wei, MD,Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianying Gao, MD,Ph.D</last_name>
    <phone>020-28687088</phone>
    <email>kevin.gao@vesber.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Posterior scleral reinforcement</keyword>
  <keyword>Macular ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

